Watson/Genelabs Prestara "approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Genelabs will conduct six-month clinical trial to confirm a positive effect for Prestara (prasterone, formerly Aslera) with bone mineral density as the primary endpoint, following an Aug. 28 "approvable" letter. Genelabs' study GL95-02 showed an effect on bone mineral density in 381 women with mild to moderate systemic lupus erythematosus; the other pivotal trial used steroid reduction as the endpoint. FDA's Arthritis Advisory Committee had expressed concern about prasterone's failure to reach prospectively defined primary endpoints at its April 19, 2001 meeting, and FDA issued a "not approvable" letter June 26, 2001. Additional analyses from GL95-02 were submitted in February 2002, showing significant increases in lumbar spine and hip bone mineral densit
You may also be interested in...
Genelabs’ decision to withdraw its European Marketing Authorization Application for the lupus therapy prasterone will not affect pursuit of FDA approval, the company maintained June 7.
The US agency has pushed to next month a public meeting on the latest incarnation of the Medical Device User Fee Amendments. The meeting will be held remotely.
Experts from the University of Chicago are advocating for helmet ventilation for COVID-19 patients. Medtech Insight spoke to acute nurse practitioner Aurika Savickaite who is helping lead an initiative to educate and raise awareness of the technology.